MA28032A1 - Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc - Google Patents

Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Info

Publication number
MA28032A1
MA28032A1 MA28865A MA28865A MA28032A1 MA 28032 A1 MA28032 A1 MA 28032A1 MA 28865 A MA28865 A MA 28865A MA 28865 A MA28865 A MA 28865A MA 28032 A1 MA28032 A1 MA 28032A1
Authority
MA
Morocco
Prior art keywords
treatment
related disorders
cyclosporins
hcv related
modified cyclosporins
Prior art date
Application number
MA28865A
Other languages
English (en)
French (fr)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28032A1 publication Critical patent/MA28032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA28865A 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc MA28032A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
MA28032A1 true MA28032A1 (fr) 2006-07-03

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28865A MA28032A1 (fr) 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Country Status (29)

Country Link
US (1) US7968518B2 (enExample)
EP (2) EP1663287B1 (enExample)
JP (1) JP4688806B2 (enExample)
KR (1) KR101116968B1 (enExample)
CN (1) CN1842343A (enExample)
AU (2) AU2004268382A1 (enExample)
BR (1) BRPI0414062B8 (enExample)
CA (1) CA2537137C (enExample)
CY (1) CY1110506T1 (enExample)
DE (1) DE602004022061D1 (enExample)
DK (1) DK1663287T3 (enExample)
ES (1) ES2328361T3 (enExample)
GB (1) GB0320638D0 (enExample)
HR (1) HRP20090535T1 (enExample)
IL (1) IL173909A (enExample)
IS (1) IS2917B (enExample)
MA (1) MA28032A1 (enExample)
MX (1) MXPA06002394A (enExample)
NO (1) NO20061479L (enExample)
NZ (1) NZ545495A (enExample)
PL (1) PL1663287T3 (enExample)
PT (1) PT1663287E (enExample)
RU (1) RU2389501C2 (enExample)
SG (1) SG149063A1 (enExample)
SI (1) SI1663287T1 (enExample)
TN (1) TNSN06071A1 (enExample)
TW (1) TWI342782B (enExample)
WO (1) WO2005021028A1 (enExample)
ZA (1) ZA200601550B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1091975B1 (fr) 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
RU2394589C2 (ru) * 2004-07-14 2010-07-20 Новартис Аг Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
CN101056648B (zh) * 2004-10-01 2012-08-15 德比奥法姆股份有限公司 [d-meala]3-[etval]4环孢菌素用于丙型肝炎感染治疗的应用以及包含所述[d-meala]3-[etval]4-环孢菌素的药物组合物
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
RU2399628C2 (ru) * 2004-10-01 2010-09-20 Скайнексис, Инк. Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
CA2587586A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
BRPI0519345A2 (pt) 2004-12-23 2009-01-20 Novartis Ag composiÇço para tratamento do hcv
US20090221598A1 (en) * 2005-06-17 2009-09-03 Kai Lin Use of Sanglifehrin in HCV
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
CN101305019B (zh) * 2005-10-26 2012-12-12 安斯泰来制药有限公司 新的环肽化合物
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
EP2073831A1 (en) * 2006-10-12 2009-07-01 Novartis AG Use of modified cyclosporins
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
EP2124992A2 (en) 2007-01-04 2009-12-02 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
BRPI0810203A2 (pt) 2007-05-02 2014-10-14 Astellas Pharma Inc Compostos peptídeos cíclicos.
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US20130190223A1 (en) * 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
CA2738280A1 (en) * 2008-09-24 2010-04-01 Astellas Pharma Inc. Peptide compound and method for producing the same
CA2741829A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
MX2013003903A (es) 2010-10-05 2013-05-20 Novartis Ag Nuevos tratamientos de infeccion por el virus de hepatitis c.
MX2013006052A (es) 2010-11-30 2013-06-18 Novartis Ag Nuevos tratamientos de la infeccion por el virus de hepatitis c.
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US20140018289A1 (en) 2011-03-31 2014-01-16 Novartis Ag New treatments of Hepatitis C virus infection
BR112013024809A2 (pt) 2011-04-01 2016-09-06 Novartis Ag tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
CA2832829A1 (en) 2011-04-13 2012-10-18 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
CN103826654A (zh) 2011-09-27 2014-05-28 诺华股份有限公司 用于治疗丙型肝炎病毒感染的阿拉泊韦
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
EP4199937A1 (en) * 2020-08-24 2023-06-28 Nanomerics Ltd Viral inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
EP1319651B1 (en) 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
EP1091975B1 (fr) 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1372695A2 (en) * 2000-10-19 2004-01-02 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN101056648B (zh) 2004-10-01 2012-08-15 德比奥法姆股份有限公司 [d-meala]3-[etval]4环孢菌素用于丙型肝炎感染治疗的应用以及包含所述[d-meala]3-[etval]4-环孢菌素的药物组合物
BRPI0519345A2 (pt) 2004-12-23 2009-01-20 Novartis Ag composiÇço para tratamento do hcv

Also Published As

Publication number Publication date
MXPA06002394A (es) 2006-06-20
CA2537137A1 (en) 2005-03-10
DE602004022061D1 (de) 2009-08-27
CN1842343A (zh) 2006-10-04
SI1663287T1 (sl) 2009-10-31
AU2004268382A1 (en) 2005-03-10
WO2005021028A1 (en) 2005-03-10
ES2328361T3 (es) 2009-11-12
IS2917B (is) 2014-12-15
NZ545495A (en) 2010-01-29
GB0320638D0 (en) 2003-10-01
EP1797892A1 (en) 2007-06-20
AU2008203031A1 (en) 2008-07-31
KR101116968B1 (ko) 2012-03-14
TW200524626A (en) 2005-08-01
PT1663287E (pt) 2009-09-03
TNSN06071A1 (en) 2007-10-03
TWI342782B (en) 2011-06-01
RU2006110533A (ru) 2007-10-10
HK1091732A1 (en) 2007-01-26
EP1663287A1 (en) 2006-06-07
EP1797892B1 (en) 2013-10-23
PL1663287T3 (pl) 2009-12-31
AU2008203031B2 (en) 2011-04-07
KR20060132798A (ko) 2006-12-22
ZA200601550B (en) 2007-05-30
IL173909A0 (en) 2006-07-05
CA2537137C (en) 2013-05-28
BRPI0414062A (pt) 2006-10-24
CY1110506T1 (el) 2015-04-29
RU2389501C2 (ru) 2010-05-20
US20070275884A1 (en) 2007-11-29
DK1663287T3 (da) 2009-11-09
JP2007504260A (ja) 2007-03-01
NO20061479L (no) 2006-06-02
SG149063A1 (en) 2009-01-29
IL173909A (en) 2011-03-31
BRPI0414062B8 (pt) 2021-05-25
US7968518B2 (en) 2011-06-28
JP4688806B2 (ja) 2011-05-25
EP1663287B1 (en) 2009-07-15
IS8371A (is) 2006-03-24
HRP20090535T1 (hr) 2009-11-30
BRPI0414062B1 (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
MA28032A1 (fr) Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1390029A4 (en) PHENYLINDOLE FOR THE TREATMENT OF HIV
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
BR0114390A (pt) éteres de 7-desmetilrapamicina
EP1646614A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
EP1838321A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
MA26221A1 (fr) Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
EP1641423A4 (en) BENZODIAZEPINE-CGRP Receptor Antagonists
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
ATE296108T1 (de) Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen
EP1753777A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING HIV INFECTION WITH TRIM5a
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
MA28038A1 (fr) Thienopyrazoles
MA30865B1 (fr) Utilisation de cyclosporines modifiees
EP1664011A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
EP2042188A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF HCV INFECTION
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
CA2306441A1 (fr) Peptides issus de gene env du virus de l'immunodeficience feline et leurs applications